COMMUNIQUÉS West-GlobeNewswire

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results
03/06/2025
Highlights of the first quarter include: Revenue of $330.8 million, an increase of 15% compared to $287.6 million in Q1 FY25. Net income of $53.9 million, an increase of 87% compared to $28.8 million in Q1 FY25, with [...]
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Windtree Announces Plan for Cryptocurrency Treasury Policy
03/06/2025
Windtree intends to accept cryptocurrency as an option for payment and also to hold as an asset WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: [...]
Merus N.V. Announces Proposed Public Offering of Common Shares
03/06/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific [...]
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
03/06/2025
Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid [...]
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
03/06/2025
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment period Favorable safety and tolerability, particularly when compared to [...]
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
03/06/2025
Based on market research, inguinal hernia repair is the most common type of hernia repair MALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company [...]
Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
03/06/2025
ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, [...]
Fortrea to Present at the Jefferies Global Healthcare Conference
03/06/2025
DURHAM, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Interim Chief Executive Officer, Peter M. Neupert and [...]
Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting
03/06/2025
BOCA RATON, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Corporation”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced the voting results of [...]
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
03/06/2025
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2025
SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Outset Medical Appoints Renee Gaeta as Chief Financial Officer
03/06/2025
SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2025
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
03/06/2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics [...]
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
03/06/2025
ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved [...]
DBV Technologies publie un amendement à son Document d’enregistrement universel 2024
03/06/2025
Châtillon, France, le 3 juin 2025 DBV Technologies publie un amendement à son Document d’enregistrement universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société [...]
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
03/06/2025
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a [...]

Pages